HPV-genotypes in high-grade intraepithelial cervical lesions in Danish women

Acta Obstetricia et Gynecologica Scandinavica

Volumn 92, Issue 9, 2013, Pages 1032-1040

  Kirschner, Benny ^a   Schledermann, Doris ^b   Holl, Katsiaryna ^c   Rosenlund, Mats ^c,d   Raillard, Alice ^e   Quint, Wim ^f   Molijn, Anco ^f   Jenkins, David ^f   Junge, Jette ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d KAROLINSKA INSTITUTE   (Sweden)

^e 4Clinics ^*  (France)

^f DDL DIAGNOSTIC LABORATORY   (Netherlands)

Author keywords

Cervical neoplasia; human papillomavirus; oncology; screening; vaccination

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; AUSTRIA; CANCER GRADING; CROSS-SECTIONAL STUDY; DENMARK; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN TISSUE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; WART VIRUS;

CERVICAL NEOPLASIA; HUMAN PAPILLOMAVIRUS; ONCOLOGY; SCREENING; VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CROSS-SECTIONAL STUDIES; DENMARK; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; UTERINE CERVICAL NEOPLASMS;

EID: 84882452624     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12162     Document Type: Article

References (25)

1. The Danish National Board of Health. Screening for cervical cancer. Copenhagen, Denmark: The Danish National Board of Health, 2012 January 11.
2. Engholm F, Ferlay J, Christensen N, Johannesen TB, Klint Å, Køtlum JE, et al. Cancer incidence, mortality, prevalence, and prediction in the Nordic countries. Association of the Nordic Cancer Registries, Danish Cancer Society. Available online at: http://www.ancr.nu.
3. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. Br Med J. 2008; 337 (Sep): a1284.
4. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121 (3): 621-32.
5. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87 (11): 796-802.
6. Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer. 2013; 132 (4): 854-67.
7. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T,. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer. 2008; 123 (8): 1864-70.
8. Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol. 1998; 153 (6): 1731-9.
9. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol. 1999; 37 (8): 2508-17.
10. Quint WG, Scholte G, van Doorn LJ, Kleter B, Smits PH, Lindeman J,. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF(10) PCR and HPV genotyping. J Pathol. 2001; 194 (1): 51-8.
11. Newcombe RG,. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998; 17 (8): 857-72.
12. Pannier-Stockman C, Segard C, Bennamar S, Gondry J, Boulanger JC, Sevestre H, et al. Prevalence of HPV genotypes determined by PCR and DNA sequencing in cervical specimens from French women with or without abnormalities. J Clin Virol. 2008; 42 (4): 353-60.
13. Clifford GM, Smith JS, Aguado T, Franceschi S,. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003; 89 (1): 101-5.
14. Baandrup L, Munk C, Andersen KK, Junge J, Iftner T, Kjaer SK,. HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3. Gynecol Oncol. 2011; 124 (2): 281-5.
15. Vinokurova S, Wentzensen N, Kraus I, Klaes R,. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008; 68 (1): 307-13.
16. Kovacs K, Varnai AD, Bollmann M, Bankfalvi A, Szendy M, Speich N, et al. Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: a 7.5-year longitudinal study in a routine cytology-based screening population in West Germany. J Med Virol. 2008; 80 (10): 1814-23.
17. Mejlhede N, Bonde J, Fomsgaard A,. High frequency of multiple HPV types in cervical specimens from Danish women. APMIS. 2009; 117 (2): 108-14.
18. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13 (1): 89-99.
19. Quint W, Jenkins D, Molijn S, Struijk L, van de Sandt M,. One virus, one lesion- individual components of CIN lesions contain a specific HPV type. J Pathol. 2012; 1 (227): 62-71.
20. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374 (9686): 301-14.
21. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364 (9447): 1757-65.
22. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367 (9518): 1247-55.
23. van Doorn LJ, Quint W, Kleter B, Molijn A, Colau B, Martin MT, et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol. 2002; 40 (3): 979-83.
24. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6 (5): 271-8.
25. Kjaer SK, Andersen ES, Djursing H, Hansen T, Jorgensen JJ, Nilas L, et al. Quadrivalent HPV 6/11/16/18 vaccine. Ugeskr Laeger. 2007; 169 (46): 3971-4.